A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.

by Tarik Asselah, Alex J Thompson, Robert Flisiak, Manuel Romero-Gomez, Diethelm Messinger, Georgios Bakalos, Mitchell L Shiffman
Published 2016-01-01

Long term changes in liver histology following treatment of chronic hepatitis C virus

by Mitchell L. Shiffman, M.D., Richard K. Sterling, Melissa Contos, Sarah Hubbard, April Long, Velimir A. Luketic, R. Todd Stravitz, Michael Fuchs, Arun J. Sanyal
Published 2014-07-01

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

by Graham R Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K Rajender Reddy, Ludovico Tallarico, Mitchell L Shiffman, Silke Ahlers, Georgios Bakalos, Tarek Hassanein, GUARD-C Study Group
Published 2016-01-01

An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.

by Thomas R O'Brien, James E Everhart, Timothy R Morgan, Anna S Lok, Raymond T Chung, Yongwu Shao, Mitchell L Shiffman, Myhanh Dotrang, John J Sninsky, Herbert L Bonkovsky, Ruth M Pfeiffer, HALT-C Trial Group
Published 2011-01-01

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

by Zobair M. Younossi, Maria Stepanova, Mazen Noureddin, Kris V. Kowdley, Simone I. Strasser, Anita Kohli, Peter Ruane, Mitchell L. Shiffman, Aasim Sheikh, Nadege Gunn, Stephen H. Caldwell, Ryan S. Huss, Robert P. Myers, Vincent Wai‐Sun Wong, Naim Alkhouri, Zachary Goodman, Rohit Loomba
Published 2021-07-01